Snake Grass: Diabetes and Metabolic Research

This claim gets far less attention than the cancer story, and the literature behind it is, perhaps surprisingly, more current: new papers on this exact question were still appearing in 2025 and 2026 as this page was being researched. It follows an evidence pattern this site has documented before on other Southeast and South Asian herbs — a real, active, growing preclinical literature, genuinely better-designed in places than the older default, and no human trial at all.

Table of Contents

  1. The Claim and Where It Comes From
  2. Reading the Rodent Literature’s Design First
  3. The Alpha-Glucosidase Mechanism: Test-Tube Assays and Docking
  4. The Mechanism Has Already Been Tested as a Drug Class
  5. Beta-Cell Protection: The Best-Designed Study
  6. Complications Beyond Glucose: Sorbitol, Arteries, Kidneys, Gums
  7. The Metformin-Combination Study
  8. Human Data: What Exists and What Does Not
  9. Verdict
  10. Key Research Papers
  11. Connections
  12. Featured Videos

The Claim and Where It Comes From

Snake grass’s main page notes that Vietnamese and Indonesian traditional use includes the leaf for diabetes, alongside fever and urinary complaints, while the more thoroughly documented Malay and Thai traditions centre on skin and topical use rather than internal metabolic complaints. So unlike the herpes-zoster claim, this one does not trace to a single well-documented regional tradition — it is a minor thread in the traditional record that modern laboratory science picked up and has run with considerably further than the tradition itself ever claimed. That is not disqualifying; it simply means the traditional-use argument carries less weight here than it does on the herpes page, and the case has to be made, if it can be made at all, on the modern data alone.

Reading the Rodent Literature’s Design First

One common model in this literature is streptozotocin (STZ)-induced diabetes — a beta-cell toxin that chemically destroys the insulin-producing cells of the pancreas, producing an insulin-deficient animal that more closely resembles type 1 diabetes, or very late-stage type 2 beta-cell failure, than the insulin-resistant state that defines type 2 diabetes at diagnosis, which is the condition most readers researching this page actually have. Of the rodent studies cited on this page, two used STZ alone: Susanti and colleagues (2024) and Mustika and colleagues (2023). Both tested leaf extract against markers of beta-cell apoptosis, oxidative stress and inflammation, and both reported protective effects — reduced apoptosis via c-Jun N-terminal kinase (JNK) pathway inhibition in the Susanti study, and reduced tumor necrosis factor-α, malondialdehyde and interleukin-6 (IL-6) with better-preserved islet architecture in the Mustika study. The details differ in ways worth seeing side by side:

These are real, useful findings about beta-cell protection under toxic stress; they are not, on their own, evidence about reversing the insulin resistance that defines most human type 2 diabetes.

Most of the type 2 diabetes studies cited here used a different model. Umar Imam and colleagues (2019), Azemi and colleagues (2021), Laorodphun and colleagues (2025) and Zhang and colleagues (2026) all combined a high-fat diet with STZ — a considerably better-regarded model that produces insulin resistance from the diet component before beta-cell stress is added, which is a closer approximation of how human type 2 diabetes actually develops. Zhang’s paper is covered in detail in the next section but one. Design quality varies across this literature more than most secondary summaries acknowledge, and it is worth checking which model a given paper used before weighing its result.

Back to Table of Contents

The Alpha-Glucosidase Mechanism: Test-Tube Assays and Docking

The most frequently proposed mechanism in this literature is inhibition of alpha-glucosidase, the intestinal brush-border enzyme that breaks complex carbohydrates into absorbable glucose — block it, and post-meal glucose absorption slows. In the C. nutans literature this mechanism has been tested with test-tube enzyme assays, and two papers added computer modelling on top. Murugesu and colleagues (2018, 2019) first measured how strongly different fractions of the leaf extract blocked the alpha-glucosidase enzyme in an in vitro (test-tube) assay, then used metabolomics — gas chromatography-mass spectrometry (GC-MS) profiling in 2018 and liquid chromatography-mass spectrometry (LC-MS) profiling in 2019 — to link that activity to particular compounds (11 candidates in 2018, four in 2019), and finally ran molecular docking simulation to estimate how those compounds could bind the enzyme. The docking step is a compound-identification exercise: it estimates binding affinity in software, and it is a genuinely useful step, but a docking score is not a measured biological effect. Both papers docked against the crystal structure of a yeast (Saccharomyces cerevisiae) isomaltase, not a human enzyme. Alam and colleagues (2017) also ran an in vitro alpha-glucosidase inhibitory assay alongside antioxidant testing and metabolite profiling on methanol extract and its fractions, reporting 72.16% inhibition by the butanol fraction in the test tube. All three therefore rest on measured enzyme inhibition rather than on a computational prediction alone — and all three are still isolated-enzyme assays, not a fed animal or a person.

A 2024 Thai laboratory study by Pechroj and colleagues found that a 95% ethanol extract of C. nutans, and more so a nanoemulsified form of it, inhibited alpha-glucosidase enzymes in the test tube and also acted against two mouth bacteria, Streptococcus mutans and Staphylococcus aureus, and their biofilms. This too is test-tube evidence only.

Back to Table of Contents

The Mechanism Has Already Been Tested as a Drug Class

As on this site’s other pages that meet this exact mechanism, the most informative fact available here comes from outside the snake-grass literature entirely. Alpha-glucosidase inhibition is not a speculative pathway — it is a licensed pharmaceutical drug class. Acarbose, miglitol and voglibose work by exactly this mechanism, at optimised, purified drug doses, and have been tested in a large trial literature with hemoglobin A1c (HbA1c) as the endpoint, summarised in multiple meta-analyses.

The size of this mechanism’s effect is therefore already measured. A 2005 Cochrane systematic review and meta-analysis of 41 trials (van de Laar and colleagues) found that, compared with placebo, alpha-glucosidase inhibitors lowered HbA1c (acarbose by 0.77%, miglitol by 0.68%); at acarbose doses above 50 mg three times a day the effect on HbA1c was the same, but side effects became more common. In a 48-week trial in China that randomised 788 people with newly diagnosed type 2 diabetes (Yang and colleagues, 2014), acarbose as the first medicine was non-inferior to metformin: HbA1c fell by 1.11% with acarbose and 1.12% with metformin at week 48. The use of alpha-glucosidase inhibitors in practice is limited by gastrointestinal side effects — flatulence, bloating, diarrhoea — that arise from the same mechanism delivering undigested carbohydrate to colonic bacteria. Two things follow, in opposite directions. Against the claim: if snake grass works partly through this mechanism, its maximum plausible effect is bounded by what a purified drug of the same class achieves, and an unstandardised leaf extract delivers an unmeasured and almost certainly small fraction of that. For fair framing: the mechanism is real, clinically validated, and not implausible pharmacology — this is a case of a genuine mechanism with an unquantified, and probably modest, dose delivered by the plant.

Back to Table of Contents

Beta-Cell Protection: The Best-Designed Study

Zhang and colleagues (2026), publishing in the Journal of Ethnopharmacology, ran the most methodologically thorough study in this entire literature to date. Using ultra-high-performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS), they first identified 45 prototype compounds from C. nutans extract actually absorbed into the bloodstream of treated animals — a meaningful check that goes beyond simply listing what is in the raw leaf, since only absorbed compounds can plausibly act systemically. They then combined network pharmacology, molecular docking, and transcriptomic sequencing to identify the chemokine signalling pathway (particularly CCL2 and CXCL12) and downstream inflammation and apoptosis pathways as the dominant mechanism, and confirmed the prediction in two systems: a combined high-fat-diet-plus-low-dose-STZ mouse model of type 2 diabetes (the better-designed model discussed above), and MIN6 pancreatic beta cells exposed to high glucose and palmitic acid to simulate the metabolic stress of diabetes in culture.

In the mouse model, C. nutans-containing treatment dose-dependently improved fasting blood glucose, oral glucose and insulin tolerance test results, and partially restored normal islet architecture, while reducing tissue and serum levels of tumor necrosis factor-α, interleukin-1 beta (IL-1β), IL-18, CCL2 and CXCL12. In the MIN6 cell system, C. nutans-conditioned serum restored cell viability, promoted insulin secretion, and reduced the same inflammatory and apoptotic markers under simulated metabolic stress. This is a coherent, multi-method, cross-validated (animal and cell, prediction and confirmation) piece of preclinical pharmacology, published in 2026, and it is the single strongest piece of mechanistic evidence in this page’s entire diabetes literature. It remains, in full, a mouse-and-cell-line study.

Back to Table of Contents

Complications Beyond Glucose: Sorbitol, Arteries, Kidneys, Gums

A cluster of rodent and cell-culture studies has looked past glucose itself to diabetes’s downstream complications, with generally consistent findings:

All three are rodent or cell-culture findings. None has a human counterpart in the indexed literature this page could find.

Back to Table of Contents

The Metformin-Combination Study

Laorodphun and colleagues (2025) tested C. nutans leaf extract combined with metformin, rather than as a standalone treatment, in a type 2 diabetic rat model, measuring renal oxidative stress, inflammation and fibrosis — diabetic kidney disease markers. They reported a synergistic improvement from the combination over metformin alone. Male Wistar rats were fed a high-fat diet for 4 weeks and then given a low dose of STZ; the diabetic rats then received the extract at 100 or 200 mg/kg a day, metformin at 100 mg/kg a day, or the extract and metformin together, by stomach tube for 4 weeks. Compared with the single treatments, the combination lowered serum creatinine and blood urea nitrogen and improved creatinine clearance (measures of how well the kidneys filter). The combination group also had lower malondialdehyde and lower inflammation and fibrosis (scarring) markers in the kidney. This is worth noting for what it is: a study explicitly designed around the extract as an adjunct to standard pharmaceutical treatment rather than a replacement for it. It is, again, a rat study.

Back to Table of Contents

Human Data: What Exists and What Does Not

A direct search of the indexed literature for Clinacanthus nutans, diabetes, and any clinical-trial publication type returns zero records. No randomised trial, no non-randomised human trial, and no published case series measuring a glycaemic outcome in a person exists for this plant, as of this page’s research. What does exist, separately, is survey data on use. In a 2013 survey of 240 people with type 2 diabetes at Malaysian primary-care clinics (Ching and colleagues), 62.5% used some form of complementary and alternative medicine, and 7.9% took Sabah snake grass — one of the four most-used herbs in the survey, after bitter gourd (30.4%), misai kucing (24.2%) and garlic (13.3%). That shows the plant is in real use among people with diabetes in Malaysia; it is not evidence that the plant works.

This absence is a finding, not a gap to apologise for on the plant’s behalf. The tools to test it are cheap, standard, and used in diabetes trials constantly: fasting glucose, hemoglobin A1c at 12 weeks, a standardised extract dose, a placebo arm. Given how active the rodent and cell literature has been through 2025 and 2026, the infrastructure and research interest clearly exist. Nobody has yet pointed a human trial at this specific plant for this specific claim.

Back to Table of Contents

Verdict

Using this site’s three-tier evidence language: a glycaemic and metabolic benefit from Clinacanthus nutans is ABSENT evidence in humans — never adequately tested, not tested-and-failed. What exists below that line is genuinely substantial for a plant of this size: an actively growing rodent and cell-culture literature, methodologically improving over time, converging on a plausible and partly cross-validated mechanism (anti-inflammatory and anti-apoptotic action protecting pancreatic beta cells, linked to chemokine signalling in the Zhang study and to the JNK pathway in the Susanti study, alongside a modest and drug-class-capped alpha-glucosidase-inhibition contribution). That is real preclinical science. No study has tested whether the plant can stand in for diabetes medicines in people; the only combination study (in rats) gave it alongside metformin, not instead of it.

Back to Table of Contents

Key Research Papers

Each paper below links to its PubMed record; the topic searches underneath return the wider literature.

  1. Zhang L et al., “Clinacanthus nutans (Burm. f.) Lindau ameliorates type 2 diabetes mellitus by suppressing chemokine-mediated inflammation and apoptosis in pancreatic β-cells: An integrated multi-omics study”, Journal of Ethnopharmacology, 2026;369:121919 — the best-designed study in this literature. — PubMed PMID: 42202914
  2. Susanti N et al., “Clinacanthus nutans leaf extract reduces pancreatic β-cell apoptosis by inhibiting JNK activation and modulating oxidative stress and inflammation in streptozotocin-induced diabetic rats”, Open Veterinary Journal, 2024;14(2):730-737. — PubMed PMID: 38549571
  3. Mustika A et al., “Clinacanthus nutans L Extracts Reduce the Serum Tumor Necrosis Factor-α, Malondialdehyde, and Interleukin-6 Levels and Improve the Langerhans Islet Area in Diabetic Rat Models”, Clinical Medicine Insights: Endocrinology and Diabetes, 2023;16:11795514231196462. — PubMed PMID: 37694133
  4. Murugesu S et al., “Characterization of α-Glucosidase Inhibitors from Clinacanthus nutans Lindau Leaves by Gas Chromatography-Mass Spectrometry-Based Metabolomics and Molecular Docking Simulation”, Molecules, 2018;23(9):2402. — PubMed PMID: 30235889
  5. Murugesu S et al., “Identification of α-glucosidase inhibitors from Clinacanthus nutans leaf extract using liquid chromatography-mass spectrometry-based metabolomics and protein-ligand interaction with molecular docking”, Journal of Pharmaceutical Analysis, 2019;9(2):91-99. — PubMed PMID: 31011465
  6. Alam MA et al., “In vitro antioxidant and, α-glucosidase inhibitory activities and comprehensive metabolite profiling of methanol extract and its fractions from Clinacanthus nutans”, BMC Complementary and Alternative Medicine, 2017;17(1):181 — enzyme-assay evidence with metabolite profiling. — PubMed PMID: 28359331
  7. Pechroj S et al., “Multifunctional Nanoemulsified Clinacanthus nutans Extract: Synergistic Anti-Pathogenic, Anti-Biofilm, Anti-Inflammatory, and Metabolic Modulation Effects against Periodontitis”, Biology (Basel), 2024;13(10):815 — test-tube study. — PubMed PMID: 39452124
  8. van de Laar FA et al., “Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis”, Diabetes Care, 2005;28(1):154-63 — the drug class that sets the ceiling on this mechanism. — PubMed PMID: 15616251
  9. Yang W et al., “Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial”, Lancet Diabetes & Endocrinology, 2014;2(1):46-55. — PubMed PMID: 24622668
  10. Umar Imam M et al., “Aqueous leaf extract of Clinacanthus nutans improved metabolic indices and sorbitol-related complications in type II diabetic rats (T2D)”, Food Science & Nutrition, 2019;7(4):1482-1493. — PubMed PMID: 31024722
  11. Azemi AK et al., “Clinacanthus nutans attenuates atherosclerosis progression in rats with type 2 diabetes by reducing vascular oxidative stress and inflammation”, Pharmaceutical Biology, 2021;59(1):1432-1440. — PubMed PMID: 34693870
  12. Thongyim S et al., “Clinacanthus nutans extract lowers periodontal inflammation under high-glucose conditions via inhibiting NF-κB signaling pathway”, Frontiers in Pharmacology, 2024;15:1410419. — PubMed PMID: 39193343
  13. Laorodphun P et al., “Synergistic amelioration of renal oxidative stress, inflammation, and fibrosis by combination of metformin and Clinacanthus nutans leave extracts in a type 2 diabetic rat model”, Frontiers in Pharmacology, 2025;16:1558341 — tested as an adjunct to metformin, not a replacement. — PubMed PMID: 40365311
  14. Ching SM et al., “Complementary alternative medicine use among patients with type 2 diabetes mellitus in the primary care setting: a cross-sectional study in Malaysia”, BMC Complementary and Alternative Medicine, 2013;13:148 — Malaysian CAM-use survey that names Sabah snake grass among the herbs used. — PubMed PMID: 23802882

PubMed Topic Searches

  1. Acarbose and HbA1c
  2. Alpha-glucosidase inhibitors in type 2 diabetes: meta-analyses
  3. Complementary medicine use in type 2 diabetes, Malaysian primary care
  4. Clinacanthus nutans, diabetes and glucose — the complete indexed literature, which shows the human-trial gap described above.

Connections

Back to Table of Contents